NSTEMI (Non-ST-segment elevation myocardial infarction)

Find all the latest content on NSTEMI published on this website.

NSTEMI is considered one of the leading causes of morbidity and mortality and its definition and treatment remains challenging requiring specific, adapted responses. Understanding different biomarkers, becoming aware of emerging new agents used in adjunctive pharmacotherapy, keeping abreast of advances in imaging techniques as well as the use of invasive imaging and functional assessment is critical. Tools, devices and techniques, and complications such as different types of vascular access or bleeding risks, can also be found here…

Filtered By

179 results

How should I treat an ambiguous LAD lesion with discrepancy between SPECT perfusion defect and FFR measurement?

02 Nov 2017

A 62-year-old male was admitted, with chest pain at rest and elevated troponins. A cardiac magnetic resonance showed signs of a recent myocardial infarction which was confirmed by OCT showing a ruptured plaque…


CULPRIT-SHOCK, EXCEL and DKCRUSH-V: TCT 2017 Late Breaking Trial Results

30 Oct 2017

Two potentially impactful clinical trials were in the limelight during day 2 of TCT 2017, as well as the quality of life analysis of a trial comparing revascularization strategies for left main disease. Let’s take a look at the results and see what their potential could be for daily practice.

Efficacy and safety of Ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54

19 Oct 2017

Dejan Milasinovic


Dejan Milasinovic

Oxygen Therapy in Suspected Acute Myocardial Infarction

30 Aug 2017

Dejan Milasinovic


Dejan Milasinovic

VALIDATE-SWEDEHEART, TROPICAL-ACS and RE-DUAL PCI: Antithrombotic Therapy takes the stage

In the accompanying editorial of COMPASS, presented at the ESC Congress 2017 in Barcelona, Eugene Braunwald vividly referred to the field of “Thrombocardiology”. Indeed, the topic of antithrombotic pharmacotherapy is now broader than ever, with plenty of drugs, indications, strategies and clinical data. Three new trials (with simultaneous publications in the New England Journal of Medicine and in The Lancet) clarify doubts, inform clinical practice and open new questions.

Ticagrelor or clopidogrel in DAPT for acute coronary syndromes: A call for a stepwise approach?

Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study

28 Aug 2017

Christopher Cook


Christopher Cook

EuroPCR 2017 Highlights: Coronary Interventions

20 May 2017 - From EUROPCR 2017

From the standpoint of 40 years of angioplasty, 20 years of physiological assessment and emerging data on a variety of topics, J. Byrne and T. Johnson review data published at EuroPCR 2017. Interest remains intense concerning bioresorbable stents (BRS) with ongoing international trials and whether evolving new devices and techniques will answer the problem of thrombosis. Complex interventions such as CTO showed interesting data and the evolution in our use of iFR or FFR continues to demonstrate the role innovation plays in our specialty, hereby better understanding physiology to improve treatment strategies and positively impacting outcome.

The role of Nurses and Allied Professionals in the management of the NSTEMI patient

19 May 2017 – From EuroPCR 2017

Lessons from PCI complications

18 May 2017 – From EuroPCR 2017